Active Pharmaceutical Ingredients and Intermediates
| Aesica | ||
Our focus now more than ever is to reflect the importance of our customers and stakeholders. |
Protection of the environment and safety of our employees and the community have always been an important part of our business. |
Aesica has world-class facilities for manufacturing products on a commercial scale to cGMP standards in campaigns from 50kg to 100mt. |
Our core technologies are a key factor in making us a first choice manufacturing supplier. |
Our development lab has state-of-the-art technology and the capacity to manufacture development compounds for use in Phase I to III clinical trials. |
|
| AqVida | ||
Aqvida offer a range of services in API sourcing and development, as well as licensing of pharmaceutical products. |
AqVida has its own product developments, such as, G-CSF (Filgrastim) and Oxaliplatin. |
AqVida is focussing on the development of innovative products, particularly biosimilars and high barrier to entry generics. |
| Argus Chemicals | ||
Argus Chemicals has expertise in areas including organophosphorous compounds, precious metals catalysts, fine chemicals for APIs, polymerisation reactions and the production of polymers for coating. |
Argus Chemicals originally produced phosphorus-based ligands for building metal catalysts; in addition, it now offers an R&D service. |
Argus Chemicals has a long experience concerning the scale up of multi-step syntheses on pilot plants. |
Argus Chemicals is also a research laboratory that specialises in chemical process development, custom synthesis and analytical method development both on lab and pilot-plant scale. |
||
| BioVectra | ||
BioVectra’s API facility, one of our three FDA-inspected manufacturing facilities (totalling 60,000ft²). |
We handle projects from shaker flask to 25,000l commercial scale, as well as cytotoxic fermentations up to 1,000l scale. |
BioVectra has significant process-scale chromatography knowledge and capacity – up to 400l commercial capacity and experience in using a variety of separation media. |
BioVectra products include a range of MPEG reagents, protein-reducing agents, peptide-coupling reagents, inducing reagents and other specialized bioprocess materials, which can be produced and supported according to cGMPs. |
||
| Euro Pharma | ||
The bulk drug intermediate products manufactured by our principals in India are supplied to the world's leading pharmaceutical companies. |
Each year we synthesise scores of new bulk drug intermediates and generic APIs in laboratories and pilot plants. |
The products that we can supply are the most competitive and cost-effective. |
Our associates have well-equipped chemical development laboratories and pilot plants. |
Euro Pharma represents leading manufacturers of bulk drug intermediate products. |
|
| Farmak | ||
Farmak's Pfaudler reactor at its multiple product facility. |
Farmak's Comber drying filter pilot-plant facility. |
Farmak's final step - the controlled area of the class C laboratory. |
Farmak's kilolab – two Buchi 60l chem reactorx (CR). |
Farmak's MAAP bag filter multiple product facility. |
|
| ICLIP - DSP-Scora | ||
ICLIP (from DSP in Israel and Scora in France) is the leading supplier of magnesium and calcium ingredients to the food and pharmaceutical industries. |
DSP-Scora magnesium products are derived from the minerals of the Dead Sea. |
DSP-Scora magnesium and calcium products the premier active pharmaceutical raw materials used in the manufacture of treatments for of stomach hyperacidity and osteoporosis. |
DSP-Scora's wide range of physical forms and properties offers the formulator great flexibility in achieving an optimal mineral supplement presentation. |
||
| Niels Clauson-Kaas (NCK) | ||
NCK is an independent chemical research and development laboratory equipped with a cGMP pilot plant. |
NCK specialises in providing pre-clinical, tox and cGMP clinical trial materials. |
NCK routinely develops analytical methods for in-process controls and intermediates, as well as development and validation of analytical test methods for final products. |
NCK routinely purifies compounds using flash chromatography. |
||
| Polpharma | ||
Polpharma pharmaceutical plant is the largest Active Pharmaceutical Ingredient (API) production facility in Poland. |
Continuous innovation is our unique way to convert human capital and invested resources into value for the company. |
Strict adherence to cGMP and GLP regulations, state-of-the-art technology and top-class equipment ensure Polpharma products are of the highest quality. |
The development of a unique and innovative method of manufacturing alendronate sodium is one of our achievements. |
API manufacturing is carried out in GMP-compliant and FDA-approved multipurpose facilities. |
|
| TAPI (Teva Active Pharmaceutical Ingredients) | ||
TAPI (Teva Active Pharmaceutical Ingredients) is a leading global supplier of active pharmaceutical ingredients. |
TAPI offers a portfolio of over 290 active pharmaceutical ingredients with superior customer service, customised solid-state specifications and unparalleled intellectual property (IP) assets. |
TAPI is a leader in the API industry through the IP value proposition we offer to our customers. |
Our advanced solid-state technology and expertise enable us to deliver customised particle size distribution (PSD), bulk density, specific surface area and more.Our advanced solid-state technology and expertise enable us to deliver customised particle size distribution (PSD), bulk density, specific surface area and more. |
Our customers are leading generic pharmaceutical companies who have found TAPI to be a reliable supplier of active pharmaceutical ingredients. |
|
| Vertellus Biomaterials | ||
Uncoated filter showing thrombus. |
PC-Coated Blood Filter. |
Controlled release drug delivery. |
Uncoated guidewire showing adhered thrombus. |
PC-coated guidewire. |
|
